# Orphazyme A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orphazyme-a-s

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.orphazyme.com
- Total disclosed funding: $62M
- Latest round: Series B (Mar 8, 2017)
- Investors on record: 7

## About

Orphazyme A/S, headquartered in Copenhagen, Denmark, is a biotechnology company specializing in the development of innovative therapies targeted at rare diseases, focusing on enzyme replacement therapies and protein aggregation disorders.Founded in 2009, Orphazyme A/S operates in the biopharmaceutical sector, concentrating on treatments for rare diseases. The firm has undergone strategic changes, including a significant pivot in its business model and focus on enzyme replacement therapies. The company has raised a total of USD 12.80 mn through various funding rounds, with its most recent deal being a Trade Sale in November 2017, where it raised DKK 600 million by offering shares on the Nasdaq Copenhagen. Its CEO is Anders Hinsby, who leads the company's initiatives from its headquarters in Copenhagen, Denmark.Orphazyme A/S focuses on developing biopharmaceuticals that target rare diseases, particularly enzyme replacement therapies. The company is engaged in creating therapies that address unmet medical needs in conditions characterized by protein aggregation. Through its commitment to research and development, Orphazyme aims to bring innovative treatments to market that improve patient outcomes.In 2023, Orphazyme A/S reported zero revenue, with an EBITDA of -USD 3,925,676.50, reflecting the company’s current financial status as it continues to navigate its strategic pathways in biotechnology.Orphazyme A/S aims to expand its product offerings and enter new markets for its enzyme replacement therapies. The company plans to leverage recent funding from its Trade Sale in November 2017 to support research and development initiatives and enhance its therapeutic pipeline. As it continues to innovate, Orphazyme is positioned to explore geographic expansion into new regions to increase its market presence and drive growth.

## Funding rounds

- Series B, Mar 8, 2017, $15M — EQT Life Sciences, SUNU Ventures
- Series B, Jan 9, 2015, $24M — Idinvest Partners, Novo Holdings, Aescap Venture, Heartcore Capital, Kurma Partners
- Series A, Sep 7, 2011, $19M — Novo Holdings, Aescap Venture, Heartcore Capital
- Seed, Feb 17, 2011, $4M — Heartcore Capital, Novo Holdings

## Investors

- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Seed, Series A, Series B
- Novo Holdings — Seed, Series A, Series B
- Aescap Venture (https://capitalatlas.ai/funds/aescap-venture) — Series A, Series B
- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series B
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- SUNU Ventures (https://capitalatlas.ai/funds/sunu-ventures) — Series B